Bard continues cardiology sell-off:
This article was originally published in Clinica
CR Bard is to make a further divestment in its cardiology sector with the sale of its global intra-aortic balloon catheter and pump business to Arrow International, of Reading, Pennsylvania, for $28 million in cash. Bard will retain around $3 million working capital. Last month, the company sold its global coronary catheter laboratory business to Arterial Vascular Engineering for $600 million (see Clinica No 816, p 1). Bard, of Murray Hill, New Jersey, says it will consider options for its remaining coronary vascular businesses over the next few months. Separately, Arrow has bought custom tubing manufacturer Medical Parameter, an $8 million turnover company based in Woburn, Massachusetts.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.